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SUMMARY 
Background: Whether healthcare workers with inflammatory bowel disease (IBD) are at increased risk 
of severe infection due to daily pathogen exposure is controversial. Aim: To assess the risk of severe 
infection in healthcare workers with IBD in a large multicentre case-control study. 
Methods: The study population comprised 482 healthcare workers with IBD from 17 centres who 
were matched for gender, age, disease subtype and year of diagnosis to 482 controls (non-healthcare 
workers with IBD). The study period was between the date of diagnosis of IBD and June 2016. Severe 
infection was defined as any community-acquired infection that required hospitalisation. 
Results: With a median follow-up of 9.3 years, 139 severe infections were recorded among cases and 
controls, including 30 Clostridium difficile infections, 33 severe viral infections, nine tuberculosis 
infections, 21 community-acquired pneumonia and 46 others.  
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No difference was observed between healthcare workers and controls regarding the overall incidence 
rates of severe infection. An increased risk of tuberculosis was noted in healthcare workers. In multi-
variate analysis in the entire study population, severe infection was associated with current exposure 
to corticosteroids (OR = 3.05,95% CI [2.06-4.52], P < 0.001), immunosuppressants (OR = 1.98, 95% 
CI [1.38-2.84], P < 0.001) and anti-TNF agents (OR = 2.93, 95% CI [2.024.27], P < 0.001) and reduced 
with Crohn's disease (OR = 0.63,95% CI [0.43-0.91], P = 0.01). Conclusions: Healthcare workers with 
IBD do not have an increased risk of severe infection compared with other patients with IBD, except 
for tuberculosis. Screening for tuberculosis exposure should be assessed in this high-risk population 
when treated with anti-TNF agents. 
1. INTRODUCTION 
The treatment methods for inflammatory bowel disease (IBD) have been dramatically altered by the 
advent of antitumour necrosis factor-α (TNF) agents within the last decades. In addition to a better 
control of the disease course resulting in fewer surgeries and, reduced need for hospitalisation and 
steroids, patients’ lives have also improved resulting in better patient-related outcomes, quality of life, 
and work productivity.1-3 Treatment strategies have then evolved with the establishment of new goals 
in the management of IBD especially for Crohn's disease and towards wider and earlier use of anti-
TNF therapy and other biological agents alone and in combination with immunomodulators.4,5 
This shift towards the step-up management paradigm has been counterbalanced by the infectious and 
neoplastic risks associated with conventional immunosuppressants and anti-TNF agents.6,7 Therefore, 
the use of immunomodulator and/or biological agents based on infectious risk stratification is 
therefore questionable. Healthcare workers represent a subgroup of patients exposed to a substantial 
risk for acquiring incidental infection due to daily and close interactions with infected patients and 
asymptomatic carriers of pathogens. A retrospective study recently reported 20 incidental cases of 
pulmonary tuberculosis even though their initial screening test results were negative, including six 
healthcare workers.8 We thus conducted a multicentre case-control study in a real-life setting with the 
aim to assess the incidence rate of severe infection in healthcare workers with IBD compared with 
other nonhealthcare worker patients with IBD, and to identify the associated predictors of severe 
infections. 
2. MATERIALS AND METHODS 
2.1. STUDY POPULATION 
The present study was a retrospective observational multicentre casecontrol study conducted in 17 
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French and Belgian academic centres affiliated with the Groupe d'Etude Thérapeutique des Affections 
Inflammatoires du tube Digestif (GETAID). From January 2015 to June 2016, investigators were asked 
to report consecutive patients with IBD followed up in their centre who were healthcare workers. 
Healthcare worker was categorised as physician, nurse, nurses’ aide, or any other healthcare 
personnel interacting with in and out-patients. 
Control patients were patients with IBD who were not healthcare workers. Control patients were 
recruited from the MICISTA registry, a tertiary monocentric clinical database of all consecutive 
patients with IBD at Saint-Antoine Hospital (Paris, France) to perform case-control matching on a 
large and exhaustive database without redundancy.9,10 
Inclusion criteria included diagnosis of IBD according to European Crohn's and Colitis Organisation 
guidelines and age at diagnosis of IBD ≥18.11,12 The protocol was both approved by the Comité 
Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé 
(CCTIRS N°15.503) and the Commission Nationale de l'Informatique et des Libertés (CNIL N°916056). 
All authors had access to the study data and reviewed and approved the final manuscript.  
2.2. DATA COLLECTION 
Investigators from the participating centres were asked to complete a standardised questionnaire. An 
on-site visit was then conducted to collect missing data from the patients’ case records. The date of 
inclusion corresponded to the date of diagnosis of IBD for cases and controls. At inclusion and until 
June 2016, the recorded data included a detailed account of the IBD diagnosis and history, smoking 
status, IBD phenotype according to the Montreal classification, medical and surgical treatment history 
and any serious infection history. For each of the patients, the disease duration was divided into 
semesters. For each semester, which was independently analysed, the occurrence of severe infection, 
smoking status, and immunosuppressive therapy (eg, steroids, thiopurines, methotrexate, anti-TNF 
therapy, ustekinumab, and anti-integrin therapy) were assessed.13 A semester was considered as a 
treatment semester if the patient received steroids, immunomodulator and/or anti-integrin therapy 
during at least 3 months within the studied semester.  
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From the diagnosis of IBD until June 2016 and for each patient, semesters in which healthcare workers 
did not work (training, sabbatical leave, retirement) and semesters after total proctocolectomy with 
ileal pouch-anal anastomosis in cases and controls with UC were not considered. 
2.3. CASE-CONTROL STUDY 
Controls were selected randomly within the MICISTA registry to match to the healthcare worker cases 
(one control for one case). MICISTA is an electronic database of the gastroenterology department of 
Saint-Antoine Hospital. All patients seen in the institution from 1994 are included in the database. 
Data regarding medical and IBD history and follow-up are prospectively coded in the system. Case-
control matching was based on gender, birth year (± 2.5 years), type of IBD and IBD diagnosis 
calendar (± 2.5 years). Data collection was performed first from the MICISTA database and from the 
patients’ case records in case of missing data. 
2.4. OUTCOMES 
The primary objective was to compare the overall incidence of severe infection in healthcare workers 
with IBD and controls. Severe infection was defined as any community-acquired infection that 
required hospitalisation including (a) Clostridium difficile infection (b) community-acquired 
pneumonia (c) Mycobacterium tuberculosis infection, (d) any other community-acquired infection 
that required hospitalisation. A specific case report form was used in case of severe infection. Patients 
were recruited from department's local databases and/or standardised hospital in-patient diagnostic 
dataset including ICD-10 codes.  
The rates of overall severe infection and any specific severe infections were expressed for 100 patient-
semester. 
2.5. STATISTICAL ANALYSIS 
Data were expressed as the means ± standard deviations or medians (interquartile range) in the case 
of continuous data. Nominal and ordinal data were compared using the Chi-square test or the Fischer's 
exact test as appropriate, whereas parametric data were compared using the Mann-Whitney tests and 
Wilcoxon's matched-pair signed-rank test as appropriate. Severe infection-free survival was calculated 
using the Kaplan-Meier method. For the comparison between semesters, an adjusted analysis 
according to the semester rank was performed to consider the influence of time (Mantel- Haenszel 
test). Factors associated with serious infection during a semester were first tested in univariate 
analysis: age, sex, IBD duration, IBD type (Crohn's disease or UC) and phenotype, familial history of 
IBD, smoking habit, extraintestinal manifestation of IBD, involvement, perianal disease, semester rank, 
healthcare worker, and IBD-related treatment (eg, steroids, immunomodulator, anti-TNF agent and, 
anti-integrin agents). Subsequent multivariate analyses using binary logistic regression models were 
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performed separately for overall severe infection and specific severe infection and adjusted for the 
abovementioned variables with an ascending stepwise procedure using the Wald test. Quantitative 
values were converted to qualitative values using the dichotomy from the median value in two distinct 
groups of equal size. Variables with P < 0.10 in the univariate analysis were considered to be potential 
adjustment variables for the multivariate analysis. All analyses were two-tailed, and P values less than 
0.05 were considered significant. All statistical evaluations were performed using SPSS statistical 
software (v17; SPSS Inc., Chicago, IL, USA). All authors had access to the study data and reviewed and 
approved the final manuscript. 
3. RESULTS 
3.1. STUDY POPULATION 
In total, 482 healthcare workers with IBD were included: 335 (69.5%) with Crohn's disease, 136 
(28.2%) with UC and 11 (2.3%) with IBDU. Patient demographic data, baseline diseases characteris-
tics, and medication history are listed in Table 1. The healthcare worker is composed of 133 (27.6%) 
physicians, 158 (32.8%) nurses, 66 (13.7%) nurses’ aides and 125 (25.9%) other healthcare profes-
sionals interacting with in and out-patients (Table S1). 
Compared with nonhealthcare worker IBD controls, healthcare workers with IBD were characterised 
by a lower frequency of smoking (27.6% vs 48.5%, P < 0.001), and more frequent use of anti-TNF 
therapy (61.0% vs 53.3%, P = 0.02) (Table 1). A slight difference in the age at diagnosis was observed 
between healthcare workers with IBD and controls (27.3 ± 11.6 vs 26.9 ± 11.7 years, P = 0.008) 
which was consistent with matching criteria (± 2.5 years). Healthcare workers with UC were more 
likely to exhibit pancolitis (60.0% vs 46.0%, P = 0.02). Healthcare workers with Crohn's disease were 
less likely to exhibit upper GI tract involvement (6.5% vs 12.9%, P = 0.006). 
3.2. INCIDENTAL CASES OF SEVERE INFECTION 
During the follow-up period, which was 9.3 [4.6-16.2] years, 22 477 semesters were analysed 
including 10 834 in the healthcare workers group and 11 643 in the control group. We collected 139 
overall severe infections in 137 case and control patients accounting for an incidence rate of 0.61 ± 
7.78 overall severe infections per 100 patient-semesters (Table 2). No deaths were noted in healthcare 
workers and the control group.  
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No difference was noted between the healthcare workers and the control group regarding the inci-
dence rate of overall severe infection (0.66 ± 8.13 vs 0.56 ± 7.45 per 100 patient-semesters, P = 0.35) 
(Table 2). The probabilities of developing severe infection in the entire study population were 1.0, 
6.1%, 10.8%, and 14.1% at 1, 5, 10, and 15 years, respectively (Figure 1). 
3.3. CHARACTERISTICS OF INCIDENTAL CASES OF SEVERE INFECTION 
The 137 severe infections were diagnosed as follows: nine tuberculosis infections, 30 Clostridium 
difficile infections, 21 community acquired pneumonia infections, 33 severe viral infections, and 46 
other severe infections requiring hospitalisation. Tuberculosis infection included two cases of 
pulmonary tuberculosis, one case of miliary tuberculosis, one case of pulmonary and hepatosplenic 
tuberculosis and five cases of primary tuberculosis infection. All cases of tuberculosis infection 
occurred in patients receiving an anti- TNF agent (9 out of 551 (1.6%) patients treated with anti-TNF 
agent) with a median delay of 16.0 [10.0-25.0] months. The five cases of primary tuberculosis infection 
were related to five healthcare workers with contacts of known tuberculosis patients with a negative 
positive interferon-gamma release assay before starting anti-TNF agent that became positive after 
contacts. The latter five patients were treated for primary tuberculosis infection with a 3 month course 
of isoniazide and rifampicine. Severe viral infections included 19 cases of Cytomegalovirus infection 
(18 primary infections and one reactivation), nine cases of severe Epstein-Barr Virus infection (nine 
primary infections and one reactivation, see Table S2), three cases of severe Varicella zoster virus 
infection (two chickenpox and one shingles) and two cases of severe Herpes Simplex Virus primary 
infection.  
The other severe infections requiring hospitalisation included enteric infection in 18 cases 
(Campylobacter sp. infection in six cases, Salmonella sp. in one case, Yersinia sp. in one case, Klebsiella 
oxytoca in one case, and undocumented infection in eight cases), pyelonephritis in six cases, erysipelas 
in four cases, dental abscess in three cases, flu-like syndrome in three cases, sinusitis in three cases, 
sigmoid diverticulitis in two cases, catheter-related bloodstream infection in two cases, acute 
cholangitis in two cases, salpingitis in one case, acute cholecystitis in one case, and oesophageal 
candidiasis in one case.  
No difference in any type of severe infection was noted between the healthcare workers and the 
control group with the exception of an increased risk of developing tuberculosis infection in the group 
of healthcare workers (0.07 ± 2.72 vs 0.009 ± 0.93 per 100 patient semesters, P = 0.02). 
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TABLE 1. Demographic and baseline disease characteristics and medication histories of 984 patients 
with inflammatory bowel disease including 482 healthcare workers 
Characteristic Healthcare workers (n = 482) Nonhealthcare workers (n = 482) P value 
Age at diagnosis, years 27.3 ± 11.6 26.9 ± 11.7 0.008 
Male gender, no (%) 355 (73.7%) 356 (73,9%) 1.00 
BMI, kg/m2 22.7 ± 4.9 22.0 ± 4.4 0.03 
History of smoking habits, no (%) 133 (27.6%) 230 (48.5%) <0.001 
Follow-up period, years 11.9 ± 9.1 11.9 ± 8.8 0.69 
Extraintestinal manifestation, no (%) 36 (7.5%) 49 (10.2%) 0.17 
Age at diagnosis, no (%) 
A1: ≤16 years 32 (6.6%) 70 (14.5%) <0.001 
A2: 17-40 years 403 (83.6%) 346 (71.8%) <0.001 
A3: >40 years 47 (9.8%) 66 (13.7%) 0.07 
Crohn's disease, no (%) 335 (69.5%) 331 (68.7%) 1.00 
Disease location, no (%) 
Ileal 125 (36.8%) 138 (40.4%) 0.35 
Colonic 86 (25.3%) 88 (25.7%) 0.93 
Ileocolonic 128 (37.6%) 116 (33.9%) 0.34 
Upper GI tract 22 (6.5%) 44 (12.9%) 0.006 
Disease phenotype, no (%) 
Non-stricturing - Non-penetrating 184 (53.8%) 194 (56.6%) 0.47 
Stricturing 84 (24.6%) 63 (18.4%) 0.06 
Penetrating 74 (21.6%) 86 (25.1%) 0.32 
Perianal disease, no (%) 106 (22.0%) 109 (22.6%) 0.88 
Inflammatory bowel disease 
undetermined, no (%) 11 (2.3%) 15 (3.1%) 0.70 
Ulcerative colitis, no (%) 136 (28.2%) 139 (28.8%) 0.89 
Proctitis 23 (12.8%) 16 (11.5%) 0.86 
Left-sided colitis 49 (27.2%) 59 (42.4%) 0.006 
Pancolitis 108 (60.0%) 64 (46.0%) 0.02 
History of intestinal resection, no (%) 133 (28.3%) 148 (30.7%) 0.44 
History of IBD treatment, no (%) 
Immunosuppressant 341 (70.7%) 379 (78.6%) 0.06 
Anti-TNF therapy 294 (61.0%) 257 (53.3%) 0.02 
Anti-integrin therapy 24 (5.0%) 19 (3.9%) 0.53 
Ustekinumab 20 (4.1%) 9 (1.9%) 0.06 
BMI, body mass index; GI, gastrointestinal; IBD, inflammatory bowel disease. Variables are presented as n (%), mean ± 
standard deviation or median (interquartile range). P values are based on a two-sided chi-square test for all categorical 
variables and on Wilcoxon's matched-pair signed-rank test for all quantitative variables. 
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3.4. PREDICTORS OF SEVERE INFECTION 
Predictors of overall severe infection were assessed in the entire study population including cases and 
controls, after dividing the follow-up period into semesters to take into account the impact of 
immunosuppressive therapy. In multivariate analysis, logistic regression analysis demonstrated that 
patients with steroids (OR = 3.05, 95% CI [2.064.52], P < 0.001), immunomodulators (OR = 1.98, 
95% CI [1.38-2.84], P < 0.001), and anti-TNF therapy (OR = 2.93, 95% CI [2.02-4.27], P < 0.001) were 
more likely to develop severe infection (Table 3). Conversely, patients with Crohn's disease (OR = 
0.63, 95% CI [0.430.91], P = 0.01) were less likely to develop severe infection. 
Additional analyses demonstrated that physicians (OR = 8.00, 95% CI [1.01-62.50], P = 0.05), steroid 
therapy (OR = 6.17, 95% CI [1.56-24.39], P = 0.009), and anti-TNF therapy (OR = 4.62, 95% CI [1.18-
18.18], P = 0.03) were associated with increased risks of developing tuberculosis infection. Patients 
with Crohn's disease (OR = 0.17, 95% CI [0.08-0.38], P < 0.001) and a BMI >20 kg/m2 (OR = 0.44, 
95% CI [0.20-0.94], P = 0.03) were less likely to develop Clostridium difficile infection whereas 
immunomodulators (OR = 2.58, 95% CI [1.19-5.59], P = 0.02) and anti-TNF therapy (OR = 2.88, 95% 
CI [1.32-6.29], P = 0.001) were associated with increased risks of developing Clostridium difficile 
infection.  
Nurses and thiopurine therapy were associated with increased risks of developing severe viral 
infection. Patients aged >50 years (OR = 4.69, 95% CI [1.97-11.11], P = 0.001), anti-TNF therapy (OR 
= 5.1, 95% CI [2.14-12.20], P < 0.001), and vedolizumab therapy (OR = 23.81, 95% CI [3.03-200.00], P 
< 0.001) were associated with increased risks of developing community-acquired pneumonia. 
FIGURE 1. Kaplan-Meier curves of 984 patients with inflammatory bowel disease assessing the 
occurrence of incident cases of severe infection  
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In our study, we provide for the first time a case-control study assessing the risk of overall severe 
infection in patients with IBD according to professional exposure to pathogens. We did not identify any 
difference between healthcare workers and control patients with the exception of increased risks of 
developing tuberculosis infection in the healthcare workers group, especially in physicians. Predictors 
of any severe infection were related to immunosuppressive therapy, age and nutritional status with 
the exception of the risk of developing tuberculosis infection in physicians and severe viral infection in 
nurses. 
Opportunistic infection remains a key safety concern in patients with IBD.14 Opportunistic infection 
may be defined as serious infections by a micro-organism that has limited pathogenic capacity under 
ordinary circumstances such as parasitic or fungal infection, and infections that occur more frequently 
or are more severe in people with weakened immune systems.14,15 In the present study, we chose to 
use the term of severe infection instead of opportunistic infection because we did not report any cases 
with rare severe infections, such as parasitic or fungal infections. Risk factors for developing 
opportunistic infection include immunosuppressive therapy (steroids ≥20 mg per day for ≥2 weeks 
and/or immunomodulator and/or biological agents), age, comorbidities, and malnutrition.14 In the 
present study, we confirmed the impact of immunosuppressive therapy on the increased risk of severe 
infection. In contrast to a recent epidemiological study, we demonstrated that patients with Crohn's 
disease were less prone to develop severe infection.16 Heterogeneity in colonic involvement between 
patients with Crohn's disease and UC may explain an increased propensity to develop Clostridium 
difficile infection in patients with Crohn's disease compared with patients with UC. Age was not a 
predictor of severe infection except for the risk of community-acquired pneumonia. However, it should 
be noted that the number of semesters in which patients were aged >60 years and >65 years were 
only 4.8% and 2.6%, respectively. 
Exposure to pathogens and geographic clustering are considered as independent risk factor of 
opportunistic infection, prompting ECCO to recommend the avoidance of endemic areas by patients 
with IBD treated with immunosuppressive therapy.14 In this setting, healthcare workers must be 
considered a population with a particular risk of opportunistic infection due to daily exposure to 
potential carriers of infectious agents that could be perceived as a contraindication to 
immunosuppressive therapy or a need for professional reorientation. In the present study, we did not 
demonstrate an increased risk of severe infection for healthcare workers with IBD as compared with 
controls. These data are reassuring for the daily management of such patients potentially considered 
at increased risk of exposure to infectious agents and may be extended to professions such as social 
workers or childcare workers. 
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TABLE 2. Incidence rates of opportunistic infection in 984 patients with inflammatory bowel disease 
based on healthcare worker status 
Characteristic 
Healthcare  
personnel (n = 482) 
Nonhealthcare  
personnel (n = 482) 
Overall study  
population (n = 984) 
P value 
Any severe infection 
72 events 
0.66 ± 8.13 
65 events 
0.56 ± 7.45 
137 events 




0.07 ± 2.72 
1 events 
0.009 ± 0.93 
9 events 
0.04 ± 2.00 
0.02 
Clostridium difficile infection 
14 events 
0.13 ± 3.59 
16 events 
0.14 ± 3.70 
30 events 





0.07 ± 2.72 
13 events 
0.11 ± 3.34 
21 events 
0.09 ± 3.06 
0.39 
Severe viral infection 
19 events 
0.18 ± 4.18 
14 events 
0.12 ± 3.47 
33 events 
0.15 ± 3.83 
0.30 
Other opportunistic  
infection requiring  
hospitalisation 
25 events 
0.23 ± 4.80 
21 events 
0.18 ± 4.24 
46 events 
0.20 ± 4.52 
0.46 
Incidence rates are expressed as events per 100 patient-semesters. 
TABLE 3. The predictors associated with occurrence of severe infection in 984 patients with 
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0.05 - - - -   
BMI >20 kg/m2 - - - - 
0.44 
[0.20-0.94] 
0.03 - - - - 
Nurse - - - - - - 
2.15 
[1.02-4.52] 
0.04 - - 
BMI, body mass index; CI, confidence interval; OR, odd ratio. 
Anti-TNF therapy is associated with an increased risk of severe infection and more specifically of 
tuberculosis infection.6,17-19 In the present study, we demonstrate that physicians with IBD exhibited 
an 8-fold increased risk of developing tuberculosis infection. Transmission of tuberculosis occurs 
through droplet nuclei aerosolised by patients with unrecognised or inappropriately treated 
tuberculosis.20 Healthcare workers exhibit an increased risk of developing latent tuberculosis 
infection.21 Indeed, since 1994, the French Code of Public Health has required Bacille Calmette-Guerin 
vaccination for all healthcare workers employed in public and private institutions, including 
students.22 In patients with IBD travelling to areas where tuberculosis is moderately to highly endemic 
who are receiving immunosuppressive therapy, tuberculosis screening test should be performed 
immediately after returning and 8-10 weeks after returning.14 Based on our results, we proposed 
performing tuberculosis screening tests in patients with IBD who are receiving immunomodulator 
therapy every 6 months, to systematically screen for any contact with patients potentially infected by 
tuberculosis and to treat incident cases of latent tuberculosis infection.23,24 In this setting, interferon-
gamma release assays have demonstrated fair agreement with the tuberculin skin test and provide 
useful information for patients with IBD.25 
Clostridium difficile infection is a common complication in IBD.26 In healthy patients, the pathogenesis 
of Clostridium difficile infection relies on disruption of the colonic microbiome equilibrium by antibi-
otic therapy.27,28 In IBD, colonic dysbiosis and exposure to immunosuppressive therapy may allow 
Clostridium difficile infection to develop in the absence of any antibiotic therapy. Whether healthcare 
workers exhibit increased carriage of Clostridium difficile and are at increased risk for developing 
Clostridium difficile infection remain unclear.29-34 In the present study, healthcare workers did not pre-
sent an increased risk of Clostridium difficile infection. An increased risk of Clostridium difficile 
infection was noted in patients treated with immunomodulators and anti-TNF therapy. An increased 
risk of Clostridium difficile infection was also noticed in patients with ulcerative colitis and IBDU 
possibility due to the heterogeneity of colonic involvement. 
Immunosuppressive therapy is often associated with subclinical reactivation of latent Herpes viridae 
infections such as Cytomegalovirus and Epstein-Barr virus.35,36  
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On the other hand, infection occurring during immunosuppressive therapy could be associated with 
severe viral infection and even haemophagocytic  lymphohistiocytosis, a rare but potentially life-
threatening complication.37-39 In the present study, healthcare workers did not exhibit an increased 
risk of developing severe viral infection. Conversely, patients treated with thiopurines and nurses 
exhibited an increased risk of developing severe viral infection. Systematic screening should be 
established before starting thiopurines especially in young males and nurses, to warrant severe 
primary infection. 
Based on two large case-control studies, patients with IBD had increased risk of pneumonia.40,41 In the 
present study, we demonstrated that an increased risk of pneumonia was associated with patients 
aged >50 years, and those treated with vedolizumab and anti-TNF. Age is a known risk for 
opportunistic infection. These data support a pre-emptive pneumococcal vaccination in patients with 
IBD, especially those aged >50 years. To the best of our knowledge, vedolizumab was not associated 
with an increased risk of infection.42-45 However, vedolizumab is associated with a specific pattern of 
incidental infection involving the upper respiratory tract and nasopharyngeal airway.46 We believe 
that patients treated with vedolizumab should also receive pneumococcal vaccination. 
Although patients were recruited from department's local databases and/or standardised hospital in-
patient diagnostic dataset, the retrospective nature of the data collection may be biased. To overcome 
this limitation, we decided to focus on severe infection meaning those that required hospitalisation. 
The results of such case-control study may also be impaired by recruitment bias. However, although 
healthcare workers were recruited from 17 academic GETAID centres, the controls were recruited 
from the Saint-Antoine Hospital MICISTA registry including 8599 patients with IBD to ensure a 
random, nonredundant and unbiased case-control matching on gender, birth year, type of IBD, and IBD 
diagnosis calendar. Finally, it is conceivable that our study may be underpowered to accurately assess 
the risk of severe infection in patients with IBD. Nevertheless, our results are close to those presented 
recently in a French nationwide population-based study.47 
We concluded that healthcare workers with IBD did not exhibit an increased risk of severe infection 
compared with controls. Special attention should be given to healthcare workers with IBD treated with 
anti-TNF based on the potential benefit of periodical screening for latent tuberculosis infection. 
Patients with IBD treated with anti- TNF and vedolizumab, especially those aged >50 years, should 
receive pneumococcal vaccination. Further studies are warranted to better understand whether 
immunosuppressive therapy should be administered according to risk stratification based on 
pathogen exposure in professionals. 
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